Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-23: Axicabtagene Ciloleucel vs Standard of Care in First-Line High-Risk Large B-Cell Lymphoma
NCT05605899Phase 3Active, not recruiting
- Sponsor
- Kite Pharma
- Start
- Feb 2023
- Primary completion
- Mar 2031
- Modality
- CAR-T Cells
- Countries
- 12
01
Overview
A Phase 3 trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Kite Pharma. Started Feb 2023; status: active, not recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05605899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605899.